Miconazole is a synthetic derivative of imidazole, a medication with a broad-spectrum antifungal agent
that is used to treat localized vaginal, skin, and nail infections. The aim of the study was to develop an
innovative technique to improve the permeability and efficacy of topical miconazole nitrate. A nanoemulgel
of miconazole nitrate was formulated by the incorporation of a nanoemulsion and a hydrogel. The
nanoemulsion was first optimized using a self-emulsifying technique, and the drug was then loaded into
the optimum formulation and evaluated prior to mixing with the hydrogel. Miconazole nitrate
nanoemulgel formulations were evaluated for their physical characteristics and antifungal activity.
Based on the results, the formulation with 0.4 % Carbopol showed the highest release profile (41.8 mg/
ml after 2 h); thus, it was chosen as the optimum formulation. A cell diffusion test was performed to
examine the ability of the Miconazole nitrate nanoemulgel to penetrate the skin and reach the bloodstream.
Percentage cumulative drug releases of 29.67 % and 23.79 % after 6 h were achieved for the
MNZ nanoemulgel and the commercial cream, Daktazol, respectively. The antifungal activity of the novel
MNZ nanoemulgel formulation was tested against Candida albicans and compared to Daktazol cream and
almond oil; the results were: 40.9 ± 2.3 mm, 25.4 ± 2.7mmand 18 ± 1.9 mm, respectively. In conclusion, a
novel MNZ nanoemulgel showing superior antifungal activity compared to that of the commercial product
has been developed. This nanotechnology technique is a step toward making pharmaceutical dosage
forms that has a lot of promise

العنوان

Saudi Pharmaceutical Journal

الناشر

Elsevier

بلد الناشر

هولندا

Indexing

Thomson Reuters

معامل التأثير

2,9

نوع المنشور

Both (Printed and Online)

المجلد

--

السنة

2023

الصفحات

526–534